Ultrasound opens brain barrier to deliver Parkinson's drug in tiny trial

NCT ID NCT04370665

Completed Disease control Sponsor: InSightec Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This pilot study tested whether a focused ultrasound device could temporarily open the blood-brain barrier to deliver the drug Cerezyme into the brains of 4 people with Parkinson's disease. The main goal was to see if the procedure was safe and could successfully get the drug into a specific brain region. Because it is a very early, small study, it does not yet show whether this approach helps Parkinson's symptoms.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Cerezyme (imiglucerase)
What this could lead to: If this works, it could show a new way to deliver drugs directly to the brain for Parkinson's disease.
What could go wrong: This is a very small pilot study with only 4 participants, focused on safety and feasibility. It is too early to know if it will improve symptoms or change the course of the disease.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for PARKINSON DISEASE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Parkinson disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

PARKINSON DISEASE

Contacts and locations

Locations

Sunnybrook Health Sciences Centre

Toronto, Ontario, M4N 3M5, Canada

More trials for these conditions

Other studies related to the condition(s) this trial covers.